Company Description
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States.
The company develops the GlucoTrack, a non-invasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain through a small sensor clipped onto the earlobe.
It is also developing the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.
The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021.
GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
| Country | United States |
| Founded | 2001 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Paul Goode |
Contact Details
Address: 301 Route 17 North, Suite 800 Rutherford, New Jersey 07070 United States | |
| Phone | 201 842 7715 |
| Website | glucotrack.com |
Stock Details
| Ticker Symbol | GCTK |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001506983 |
| CUSIP Number | 45824Q804 |
| ISIN Number | US45824Q8042 |
| Employer ID | 98-0668934 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Paul V. Goode Ph.D. | Chief Executive Officer, President and Director |
| Avner Gal MBA, MSc.EE | Co-Founder, Chairman Emeritus, Consultant and Member of Scientific and Clinical Advisory Board |
| David Malka BA | Co-Founder |
| Peter C. Wulff | Chief Financial Officer, Treasurer and Secretary |
| Mark Tapsak Ph.D. | Chief Scientific Officer |
| Drinda Benjamin | Vice President of Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 3, 2025 | DEF 14A | Other definitive proxy statements |
| Sep 29, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Sep 23, 2025 | PRE 14A | Other preliminary proxy statements |
| Sep 12, 2025 | 8-K | Current Report |
| Sep 11, 2025 | 8-K | Current Report |
| Sep 5, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 14, 2025 | 10-Q | Quarterly Report |
| Aug 14, 2025 | 8-K | Current Report |
| Aug 6, 2025 | 8-K | Current Report |
| Jul 31, 2025 | 8-K | Current Report |